On a mis­sion to treat pa­tients not cov­ered by Lux­tur­na, Ho­ra­ma re­fu­els with a Se­ries B ex­pan­sion and a new name

About four years af­ter clos­ing its Se­ries B round the first time, Ho­ra­ma is adding an­oth­er $25.1 mil­lion to its cof­fers for its work on a next-gen gene ther­a­py that could treat re­tini­tis pig­men­tosa pa­tients not cov­ered by Roche’s Lux­tur­na — and it’s sport­ing a new name to boot.

The French biotech, now called Coave Ther­a­peu­tics, has ex­pand­ed its Se­ries B round, bring­ing its to­tal raise to $39 mil­lion, CEO Rodolphe Cler­val an­nounced ear­ly Wednes­day morn­ing. The lat­est round was led by Ser­o­ba Life Sci­ences, with a hand from Théa Open In­no­va­tion, eu­reKARE, Fund+, Omnes Cap­i­tal, V-Bio Ven­tures, Kur­ma Part­ners, Id­in­vest, GO Cap­i­tal, and Sham In­no­va­tion San­té/Turenne.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER